Abstract
Nearly 259 million people are living with chronic hepatitis B globally, with just 7 million of them receiving life-saving treatment. In 2022, 83% of all viral hepatitis deaths were attributed to hepatitis B. Despite the availability of effective vaccines, diagnostics, and treatments, hepatitis B continues to be underprioritized on the global health agenda. Stigma and discrimination have been pervasive and entrenched in numerous countries, resulting in economic and social setbacks for people living with hepatitis B. Through the personal stories of several individuals living with hepatitis B worldwide, this article explores the question: Why does hepatitis B remain underprioritized? It walks through the roadblocks hindering the progress towards hepatitis B elimination efforts and draws lessons from other diseases - such as human immunodeficiency virus, coronavirus disease 2019, and Ebola, where advocacy, political commitment, and sustained funding led to meaningful progress in prevention, diagnosis, and treatment. This evidence-backed perspective is based on decades-long efforts of the Hepatitis B Foundation, collaborating with international partners to prevent new infections, documenting the lived experiences of those living with hepatitis B and supporting them, and advocating for better care and policies affecting those impacted by the disease. Beyond identifying persistent challenges to eliminating hepatitis B, the article succinctly issues a call to action for greater investment, cross-sector collaboration, integration of disease programs to improve efficiency, and inclusion of patient-reported outcomes in hepatitis B management and evaluation, to better support those living with hepatitis B.